MG
SNDX icon

Michael Gelband’s Syndax Pharmaceuticals SNDX Stock Holding History

Michael Gelband’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-105,051
Closed -$2.45M – 2031
2026
Q1 		$2.45M Sell
105,051
-449,710
-81% -$9.77M 0.02% 708
2025
Q4 		$11.7M Buy
554,761
+482,297
+666% +$8.41M 0.09% 212
2025
Q3 		$1.11M Buy
+72,464
New +$948K 0.01% 928
2025
Q2 		– Sell
-314,407
Closed -$3.86M – 1935
2025
Q1 		$3.86M Buy
314,407
+165,839
+112% +$2.34M 0.04% 498
2024
Q4 		$1.96M Sell
148,568
-169,826
-53% -$2.91M 0.01% 715
2024
Q3 		$6.13M Sell
318,394
-307,329
-49% -$6.35M 0.04% 352
2024
Q2 		$12.8M Buy
625,723
+339,393
+119% +$7.1M 0.09% 209
2024
Q1 		$6.82M Sell
286,330
-66,922
-19% -$1.49M 0.05% 300
2023
Q4 		$7.63M Buy
353,252
+197,538
+127% +$3.04M 0.05% 251
2023
Q3 		$2.26M Sell
155,714
-50,004
-24% -$946K 0.02% 635
2023
Q2 		$4.31M Buy
205,718
+143,845
+232% +$2.99M 0.04% 503
2023
Q1 		$1.31M Buy
+61,873
New +$1.54M 0.01% 1043
2022
Q4 		– Sell
-58,466
Closed -$1.41M – 2095
2022
Q3 		$1.41M Sell
58,466
-1,891
-3% -$42.4K 0.02% 959
2022
Q2 		$1.16M Buy
60,357
+40,684
+207% +$678K 0.01% 1010
2022
Q1 		$342K Buy
+19,673
New +$331K ﹤0.01% 1715
2021
Q2 		– Sell
-10,359
Closed -$232K – 2767
2021
Q1 		$232K Buy
+10,359
New +$234K ﹤0.01% 1813

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Michael Gelband's SNDX Position: Q2 2026 in Review

Michael Gelband sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 105,051 shares — an estimated $2.45M sold.

Michael Gelband first reported a position in SNDX in Q1 2021 and held it in 16 quarters. The position peaked at $12.8M in Q2 2024. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Michael Gelband reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 105,051 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.45M.
  • Michael Gelband first reported a position in Syndax Pharmaceuticals in Q1 2021 and held it in 16 quarters.
  • Michael Gelband's Syndax Pharmaceuticals position peaked at $12.8M in Q2 2024.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.